Professional Summary »
Specializing In »
Practice Locations »
Patient Ratings »
Referring Physicians »
Biography
Dr. Arai has formal training in clinical research with a Masters in Epidemiology from Stanford University. She has a clinical practice seeing all diseases in hematopoietic cell transplantation, with a clinical research focus on the prevention and treatment of post-transplant complications.
View Full Biography »
Professional Summary
Education & Certifications
- Board Certification: American Board of Internal Medicine, Hematology (2019)
- Medical Education: Dartmouth Geisel School of Medicine Office of the Registrar (1991) NH
- Fellowship: Johns Hopkins Hospital (1999) MD
- Residency: Strong Memorial Hospital (1995) NY
- Fellowship: Mount Sinai Medical Center (1998) NY
- Internship: Strong Memorial Hospital (1993) NY
- MS, Stanford University, Epidemiology (2006)
- MD, Dartmouth Medical School
Awards & Memberships
- "A phase I/II study of post-transplant autologous CIK cells for high-risk hematologic malignancies", Cancer Treatment Research Foundation (2005-2009)
- K23-"Reduce GVHD and Relapse using Ex-Vivo Expanded Allogeneic Cell Therapy", NIH (2003-2008)
Publications
-
A cost-effectiveness analysis of adjuvant trastuzumab regimens in early HER2/neu-positive breast cancer
Kurian, A. W., Newton Thompson, R., Gaw, A. F., Arai, S., Ortiz, R., & Garber, A. M. (2007). A cost-effectiveness analysis of adjuvant trastuzumab regimens in early HER2/neu-positive breast cancer. JOURNAL OF CLINICAL ONCOLOGY, 25(6), 634–41. -
Infusion of the allogeneic cell line NK-92 in patients with advanced renal cell cancer or melanoma: a phase I trial
Arai, S., Meagher, R., Swearingen, M., Myint, H., Rich, E., Martinson, J., & Klingemann, H. (2008). Infusion of the allogeneic cell line NK-92 in patients with advanced renal cell cancer or melanoma: a phase I trial. CYTOTHERAPY, 10(6), 625–632. -
TLI and ATG conditioning with low risk of graft-versus-host disease retains antitumor reactions after allogeneic hematopoietic cell transplantation from related and unrelated donors
Kohrt, H. E., Turnbull, B. B., Heydari, K., Shizuru, J. A., Laport, G. G., Miklos, D. B., … Lowsky, R. (2009). TLI and ATG conditioning with low risk of graft-versus-host disease retains antitumor reactions after allogeneic hematopoietic cell transplantation from related and unrelated donors. BLOOD, 114(5), 1099–1109. -
Phase I/II Trial of GN-BVC, a Gemcitabine and Vinorelbine-Containing Conditioning Regimen for Autologous Hematopoietic Cell Transplantation in Recurrent and Refractory Hodgkin Lymphoma
Arai, S., Letsinger, R., Wong, R. M., Johnston, L. J., Laport, G. G., Lowsky, R., … Horning, S. J. (2010). Phase I/II Trial of GN-BVC, a Gemcitabine and Vinorelbine-Containing Conditioning Regimen for Autologous Hematopoietic Cell Transplantation in Recurrent and Refractory Hodgkin Lymphoma. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 16(8), 1145–54. -
Rituximab in hematopoietic cell transplantation
Arai, S., & Miklos, D. B. (2010). Rituximab in hematopoietic cell transplantation. EXPERT OPINION ON BIOLOGICAL THERAPY, 10(6), 971–82. -
Long-term outcomes in patients with high-risk myeloid malignancies following matched related donor hematopoietic cell transplantation with myeloablative conditioning of BU, etoposide and CY
Naik, S., Wong, R., Arai, S., Brown, J., Laport, G., Lowsky, R., … Johnston, L. (2011). Long-term outcomes in patients with high-risk myeloid malignancies following matched related donor hematopoietic cell transplantation with myeloablative conditioning of BU, etoposide and CY. BONE MARROW TRANSPLANTATION, 46(2), 192–99. -
Complete donor T-cell engraftment 30 days after allogeneic transplantation predicts molecular remission in high-risk chronic lymphocytic leukaemia
Jones, C. D., Arai, S., Lowsky, R., Tyan, D. B., Zehnder, J. L., & Miklos, D. B. (2010). Complete donor T-cell engraftment 30 days after allogeneic transplantation predicts molecular remission in high-risk chronic lymphocytic leukaemia. BRITISH JOURNAL OF HAEMATOLOGY, 150(5), 637–39. -
Early CMV Viremia Is Associated with Impaired Viral Control following Nonmyeloablative Hematopoietic Cell Transplantation with a Total Lymphoid Irradiation and Antithymocyte Globulin Preparative Regimen
Schaenman, J. M., Shashidhar, S., Rhee, C., Wong, J., Navato, S., Wong, R. M., … Brown, J. M. (2011). Early CMV Viremia Is Associated with Impaired Viral Control following Nonmyeloablative Hematopoietic Cell Transplantation with a Total Lymphoid Irradiation and Antithymocyte Globulin Preparative Regimen. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 17(5), 693–702. -
Patient-reported quality of life is associated with severity of chronic graft-versus-host disease as measured by NIH criteria: report on baseline data from the Chronic GVHD Consortium
Pidala, J., Kurland, B., Chai, X., Majhail, N., Weisdorf, D. J., Pavletic, S., … Lee, S. J. (2011). Patient-reported quality of life is associated with severity of chronic graft-versus-host disease as measured by NIH criteria: report on baseline data from the Chronic GVHD Consortium. BLOOD, 117(17), 4651–57. -
Sirolimus and mycophenolate mofetil as GVHD prophylaxis in myeloablative, matched-related donor hematopoietic cell transplantation
Johnston, L., Florek, M., Armstrong, R., McCune, J. S., Arai, S., Brown, J., … Negrin, R. (2012). Sirolimus and mycophenolate mofetil as GVHD prophylaxis in myeloablative, matched-related donor hematopoietic cell transplantation. BONE MARROW TRANSPLANTATION, 47(4), 581–88. -
Tandem chemo-mobilization followed by high-dose melphalan and carmustine with single autologous hematopoietic cell transplantation for multiple myeloma
Chen, A. I., Negrin, R. S., McMillan, A., Shizuru, J. A., JOHNSTON, L. J., Lowsky, R., … Stockerl-Goldstein, K. (2012). Tandem chemo-mobilization followed by high-dose melphalan and carmustine with single autologous hematopoietic cell transplantation for multiple myeloma. BONE MARROW TRANSPLANTATION, 47(4), 516–21. -
Adoptive Immunotherapy with Cytokine-Induced Killer Cells for Patients with Relapsed Hematologic Malignancies after Allogeneic Hematopoietic Cell Transplantation
Laport, G. G., Sheehan, K., Baker, J., Armstrong, R., Wong, R. M., Lowsky, R., … Negrin, R. S. (2011). Adoptive Immunotherapy with Cytokine-Induced Killer Cells for Patients with Relapsed Hematologic Malignancies after Allogeneic Hematopoietic Cell Transplantation. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 17(11), 1679–87. -
Global and organ-specific chronic graft-versus-host disease severity according to the 2005 NIH Consensus Criteria
Arai, S., Jagasia, M., Storer, B., Chai, X., Pidala, J., Cutler, C., … Lee, S. J. (2011). Global and organ-specific chronic graft-versus-host disease severity according to the 2005 NIH Consensus Criteria. BLOOD, 118(15), 4242–49. -
A phase 1 study of imatinib for corticosteroid-dependent/refractory chronic graft-versus-host disease: response does not correlate with anti-PDGFRA antibodies
Chen, G. L., Arai, S., Flowers, M. E. D., Otani, J. M., Qiu, J., Cheng, E. C., … Miklos, D. B. (2011). A phase 1 study of imatinib for corticosteroid-dependent/refractory chronic graft-versus-host disease: response does not correlate with anti-PDGFRA antibodies. BLOOD, 118(15), 4070–78. -
Heart transplantation and cardiac amyloidosis: Approach to screening and novel management strategies
Varr, B. C., Liedtke, M., Arai, S., Lafayette, R. A., Schrier, S. L., & Witteles, R. M. (2012). Heart transplantation and cardiac amyloidosis: Approach to screening and novel management strategies. JOURNAL OF HEART AND LUNG TRANSPLANTATION, 31(3), 325–31. -
Overlap subtype of chronic graft-versus-host disease is associated with an adverse prognosis, functional impairment, and inferior patient-reported outcomes: a Chronic Graft-versus-Host Disease Consortium study
Pidala, J., Vogelsang, G., Martin, P., Chai, X., Storer, B., Pavletic, S., … Lee, S. J. (2012). Overlap subtype of chronic graft-versus-host disease is associated with an adverse prognosis, functional impairment, and inferior patient-reported outcomes: a Chronic Graft-versus-Host Disease Consortium study. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 97(3), 451–58. -
Prophylactic rituximab after allogeneic transplantation decreases B-cell alloimmunity with low chronic GVHD incidence
Arai, S., Sahaf, B., Narasimhan, B., Chen, G. L., Jones, C. D., Lowsky, R., … Miklos, D. B. (2012). Prophylactic rituximab after allogeneic transplantation decreases B-cell alloimmunity with low chronic GVHD incidence. BLOOD, 119(25), 6145–54. -
More Than a Frog in the Throat A Case Series and Review of Localized Laryngeal Amyloidosis
Stevenson, R., Witteles, R., Damrose, E., Arai, S., Lafayette, R. A., Schrier, S., … Liedtke, M. (2012). More Than a Frog in the Throat A Case Series and Review of Localized Laryngeal Amyloidosis. ARCHIVES OF OTOLARYNGOLOGY-HEAD & NECK SURGERY, 138(5), 509–11. -
Correlation between NIH composite skin score, patient-reported skin score, and outcome: results from the Chronic GVHD Consortium
Jacobsohn, D. A., Kurland, B. F., Pidala, J., Inamoto, Y., Chai, X., Palmer, J. M., … Flowers, M. E. D. (2012). Correlation between NIH composite skin score, patient-reported skin score, and outcome: results from the Chronic GVHD Consortium. BLOOD, 120(13), 2545–52. -
H-Y antigen-binding B cells develop in male recipients of female hematopoietic cells and associate with chronic graft vs. host disease
Sahaf, B., Yang, Y., Arai, S., Herzenberg, L. A., Herzenberg, L. A., & Miklos, D. B. (2013). H-Y antigen-binding B cells develop in male recipients of female hematopoietic cells and associate with chronic graft vs. host disease. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 110(8), 3005–10. -
The prognostic value of diagnosing concurrent multiple myeloma in immunoglobulin light chain amyloidosis
Dinner, S., Witteles, W., Witteles, R., Lam, A., Arai, S., Lafayette, R., … Liedtke, M. (2013). The prognostic value of diagnosing concurrent multiple myeloma in immunoglobulin light chain amyloidosis. BRITISH JOURNAL OF HAEMATOLOGY, 161(3), 367–72. -
Lenalidomide, melphalan and dexamethasone in a population of patients with immunoglobulin light chain amyloidosis with high rates of advanced cardiac involvement.
Dinner, S., Witteles, W., Afghahi, A., Witteles, R., Arai, S., Lafayette, R., … Liedtke, M. (2013). Lenalidomide, melphalan and dexamethasone in a population of patients with immunoglobulin light chain amyloidosis with high rates of advanced cardiac involvement. Haematologica, 98(10), 1593–99. -
Natural killer cells: can they be useful as adoptive immunotherapy for cancer?
Natural killer cells: can they be useful as adoptive immunotherapy for cancer? (2005). Expert Opin Biol Ther, 5. -
Association of Foxp3 regulatory gene expression and graft-versus-host disease
Association of Foxp3 regulatory gene expression and graft-versus-host disease. (2004). Blood, 104. -
Poor outcome in steroid refractory GVHD with ATG treatment
Poor outcome in steroid refractory GVHD with ATG treatment. (2002). Biol Blood Marrow Transplant, 8. -
von Willebrand factor-cleaving protease activity and proteolysis of von Willebrand factor in bone marrow transplant-associated thrombotic microangiopathy
von Willebrand factor-cleaving protease activity and proteolysis of von Willebrand factor in bone marrow transplant-associated thrombotic microangiopathy. (2001). The Hematology Journal, 2. -
Fludarabine-Based Conditioning for Marrow Transplantation from Unrelated Donors in Severe Aplastic Anemia: Early Results of a Cyclophosphamide Dose Deescalation Study Show Life-Threatening Adverse Events at Predefined Cyclophosphamide Dose Levels
Tolar, J., Deeg, H. J., Arai, S., Horwitz, M., Antin, J. H., McCarty, J. M., … Anderlini, P. (2012). Fludarabine-Based Conditioning for Marrow Transplantation from Unrelated Donors in Severe Aplastic Anemia: Early Results of a Cyclophosphamide Dose Deescalation Study Show Life-Threatening Adverse Events at Predefined Cyclophosphamide Dose Levels. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 18(7), 1007–11. -
Mycophenolate mofetil for the prevention and treatment of graft-versus-host disease following stem cell transplantation: preliminary findings
Vogelsang, G. B., & Arai, S. (2001). Mycophenolate mofetil for the prevention and treatment of graft-versus-host disease following stem cell transplantation: preliminary findings. BONE MARROW TRANSPLANTATION, 27(12), 1255–1262. -
Management of graft-versus-host disease
Arai, S., & Vogelsang, G. B. (2000). Management of graft-versus-host disease. BLOOD REVIEWS, 14(4), 190–204. -
Role of immunotherapy in stem cell transplantation
Arai, S., & Klingemann, H. G. (2003). Role of immunotherapy in stem cell transplantation. INTERNATIONAL JOURNAL OF HEMATOLOGY, 77(1), 22–28. -
Successful Surgical and Medical Treatment of Rhizopus Osteomyelitis Following Hematopoietic Cell Transplantation
Vashi, N., Avedian, R., Brown, J., & Arai, S. (2012). Successful Surgical and Medical Treatment of Rhizopus Osteomyelitis Following Hematopoietic Cell Transplantation. ORTHOPEDICS, 35(10), E1556–E1561. -
Short tandem repeat and human leukocyte antigen mutations or losses confound engraftment and typing analysis in hematopoietic stem cell transplants
Pereira, S., Vayntrub, T., Hiraki, D. D., Cherry, A. M., Arai, S., Dvorak, C. C., & Grumet, F. C. (2011). Short tandem repeat and human leukocyte antigen mutations or losses confound engraftment and typing analysis in hematopoietic stem cell transplants. HUMAN IMMUNOLOGY, 72(6), 503–509. -
High prevalence of metabolic syndrome after allogeneic hematopoietic cell transplantation
Majhail, N. S., Flowers, M. E., Ness, K. K., Jagasia, M., Carpenter, P. A., Arora, M., … Burns, L. J. (2009). High prevalence of metabolic syndrome after allogeneic hematopoietic cell transplantation. BONE MARROW TRANSPLANTATION, 43(1), 49–54. -
Regulation of OX40 gene expression in graft-versus- host disease
Miura, Y., Thoburn, C. J., Bright, E. C., Arai, S., & Hess, A. D. (2005). Regulation of OX40 gene expression in graft-versus- host disease. TRANSPLANTATION PROCEEDINGS, 37(1), 57–61. -
Measurement of oral chronic GVHD: results from the Chronic GVHD Consortium
Treister, N., Chai, X., Kurland, B., Pavletic, S., Weisdorf, D., Pidala, J., … Cutler, C. (2013). Measurement of oral chronic GVHD: results from the Chronic GVHD Consortium. BONE MARROW TRANSPLANTATION, 48(8), 1123–28. -
Implantable cardioverter-defibrillator placement in patients with cardiac amyloidosis
Varr, B. C., Zarafshar, S., Coakley, T., Liedtke, M., Lafayette, R. A., Arai, S., … Witteles, R. M. (2014). Implantable cardioverter-defibrillator placement in patients with cardiac amyloidosis. HEART RHYTHM, 11(1), 158–62. -
Minimal residual disease monitoring with high-throughput sequencing of T cell receptors in cutaneous T cell lymphoma.
Weng, W.-K., Armstrong, R., Arai, S., Desmarais, C., Hoppe, R., & Kim, Y. H. (2013). Minimal residual disease monitoring with high-throughput sequencing of T cell receptors in cutaneous T cell lymphoma. Science Translational Medicine, 5(214), 214ra171-? -
Comorbidity burden in patients with chronic GVHD
Wood, W. A., Chai, X., Weisdorf, D., Martin, P. J., Cutler, C., INAMOTO, Y., … Mitchell, S. (2013). Comorbidity burden in patients with chronic GVHD. BONE MARROW TRANSPLANTATION, 48(11), 1429–36. -
Pulmonary symptoms measured by the national institutes of health lung score predict overall survival, nonrelapse mortality, and patient-reported outcomes in chronic graft-versus-host disease.
Palmer, J., Williams, K., Inamoto, Y., Chai, X., Martin, P. J., Tomas, L. S., … Lee, S. J. (2014). Pulmonary symptoms measured by the national institutes of health lung score predict overall survival, nonrelapse mortality, and patient-reported outcomes in chronic graft-versus-host disease. Biology of Blood and Marrow Transplantation , 20(3), 337–44. -
Total lymphoid irradiation-antithymocyte globulin conditioning and allogeneic transplantation for patients with myelodysplastic syndromes and myeloproliferative neoplasms.
Benjamin, J., Chhabra, S., Kohrt, H. E., Lavori, P., Laport, G. G., Arai, S., … Lowsky, R. (2014). Total lymphoid irradiation-antithymocyte globulin conditioning and allogeneic transplantation for patients with myelodysplastic syndromes and myeloproliferative neoplasms. Biology of Blood and Marrow Transplantation , 20(6), 837–43. -
Minimal Residual Disease Monitoring with High-Throughput Sequencing of T Cell Receptors in Cutaneous T Cell Lymphoma
Weng, W.-K., Armstrong, R., Arai, S., Desmarais, C., Hoppe, R., & Kim, Y. H. (2013). Minimal Residual Disease Monitoring with High-Throughput Sequencing of T Cell Receptors in Cutaneous T Cell Lymphoma. SCIENCE TRANSLATIONAL MEDICINE, 5(214). -
Assessment of Joint and Fascia Manifestations in Chronic Graft-Versus-Host Disease
Inamoto, Y., Pidala, J., Chai, X., Kurland, B. F., Weisdorf, D., Flowers, M. E. D., … Carpenter, P. A. (2014). Assessment of Joint and Fascia Manifestations in Chronic Graft-Versus-Host Disease. ARTHRITIS & RHEUMATOLOGY, 66(4), 1044–52. -
Association of severity of organ involvement with mortality and recurrent malignancy in patients with chronic graft-versus-host disease
Inamoto, Y., Martin, P. J., Storer, B. E., Palmer, J., Weisdorf, D. J., Pidala, J., … Lee, S. J. (2014). Association of severity of organ involvement with mortality and recurrent malignancy in patients with chronic graft-versus-host disease. HAEMATOLOGICA, 99(10), 1618–23. -
Increasing Incidence of Chronic Graft-versus-Host Disease in Allogeneic Transplantation: A Report from the Center for International Blood and Marrow Transplant Research.
Arai, S., Arora, M., Wang, T., Spellman, S. R., He, W., Couriel, D. R., … Pavletic, S. Z. (2015). Increasing Incidence of Chronic Graft-versus-Host Disease in Allogeneic Transplantation: A Report from the Center for International Blood and Marrow Transplant Research. Biology of Blood and Marrow Transplantation , 21(2), 266–74. -
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report.
Jagasia, M. H., Greinix, H. T., Arora, M., Williams, K. M., Wolff, D., Cowen, E. W., … Flowers, M. E. D. (2015). National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report. Biology of Blood and Marrow Transplantation , 21(3), 389–401 e1. -
Outcomes after heart transplantation for amyloid cardiomyopathy in the modern era.
Davis, M. K., Kale, P., Liedtke, M., Schrier, S., Arai, S., Wheeler, M., … Witteles, R. M. (2015). Outcomes after heart transplantation for amyloid cardiomyopathy in the modern era. American Journal of Transplantation , 15(3), 650–58. -
Allogeneic hematopoietic cell transplant for normal karyotype AML: indirect evidence of selection for adverse molecular profile.
Percival, M.-E. M., Medeiros, B. C., Tian, L., Robeson, S., Laport, G. G., Johnston, L. J., … Lowsky, R. (2015). Allogeneic hematopoietic cell transplant for normal karyotype AML: indirect evidence of selection for adverse molecular profile. Bone Marrow Transplantation. -
Clinical activity of ponatinib in a patient with FGFR1-rearranged mixed-phenotype acute leukemia.
Khodadoust, M. S., Luo, B., Medeiros, B. C., Johnson, R. C., Ewalt, M. D., Schalkwyk, A. S., … Gotlib, J. (2016). Clinical activity of ponatinib in a patient with FGFR1-rearranged mixed-phenotype acute leukemia. Leukemia, 30(4), 947–50. -
Failure-free survival in a prospective cohort of patients with chronic graft-versus-host disease
Palmer, J., Chai, X., Martin, P. J., Weisdorf, D., Inamoto, Y., Pidala, J., … Lee, S. J. (2015). Failure-free survival in a prospective cohort of patients with chronic graft-versus-host disease. HAEMATOLOGICA, 100(5), 690–95. -
Association of severity of organ involvement with mortality and recurrent malignancy in patients with chronic graft-versus-host disease.
Inamoto, Y., Martin, P. J., Storer, B. E., Palmer, J., Weisdorf, D. J., Pidala, J., … Lee, S. J. (2014). Association of severity of organ involvement with mortality and recurrent malignancy in patients with chronic graft-versus-host disease. Haematologica, 99(10), 1618–23. -
Cyclophosphamide conditioning in patients with severe aplastic anaemia given unrelated marrow transplantation: a phase 1-2 dose de-escalation study
Anderlini, P., Wu, J., Gersten, I., Ewell, M., Tolar, J., Antin, J. H., … Eapen, M. (2015). Cyclophosphamide conditioning in patients with severe aplastic anaemia given unrelated marrow transplantation: a phase 1-2 dose de-escalation study. LANCET HAEMATOLOGY, 2(9), E367–E375. -
Allogeneic hematopoietic cell transplantation after failed autologous transplant for lymphoma using TLI and anti-thymocyte globulin conditioning
Rezvani, A. R., Kanate, A. S., Efron, B., Chhabra, S., Kohrt, H. E., Shizuru, J. A., … Lowsky, R. (2015). Allogeneic hematopoietic cell transplantation after failed autologous transplant for lymphoma using TLI and anti-thymocyte globulin conditioning. BONE MARROW TRANSPLANTATION, 50(10), 1286–92. -
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report.
Jagasia, M. H., Greinix, H. T., Arora, M., Williams, K. M., Wolff, D., Cowen, E. W., … Flowers, M. E. D. (2015). National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report. Biology of Blood and Marrow Transplantation , 21(3), 389–401 e1. -
Late Acute and Chronic Graft-versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation.
Arora, M., Cutler, C. S., Jagasia, M. H., Pidala, J., Chai, X., Martin, P. J., … Lee, S. J. (2016). Late Acute and Chronic Graft-versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation , 22(3), 449–55. -
A Randomized Phase II Crossover Study of Imatinib or Rituximab for Cutaneous Sclerosis after Hematopoietic Cell Transplantation.
Arai, S., Pidala, J., Pusic, I., Chai, X., Jaglowski, S., Khera, N., … Flowers, M. E. D. (2016). A Randomized Phase II Crossover Study of Imatinib or Rituximab for Cutaneous Sclerosis after Hematopoietic Cell Transplantation. Clinical Cancer Research , 22(2), 319–27. -
Long-awaited news for hepatic veno-occlusive disease.
Arai, S. (2016). Long-awaited news for hepatic veno-occlusive disease. Blood, 127(13), 1630–31. -
Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure.
Richardson, P. G., Riches, M. L., Kernan, N. A., Brochstein, J. A., Mineishi, S., Termuhlen, A. M., … Soiffer, R. J. (2016). Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure. Blood, 127(13), 1656–65. -
Oral chronic GVHD outcomes and resource utilization: a subanalysis from the chronic GVHD consortium.
Yuan, A., Chai, X., Martins, F., Arai, S., Arora, M., Correa, M. E., … Treister, N. S. (2016). Oral chronic GVHD outcomes and resource utilization: a subanalysis from the chronic GVHD consortium. Oral Diseases, 22(3), 235–40. -
Clinicopathologic Threshold of Acute Colorectal Graft-versus-Host Disease
Gomez, A. J., Arai, S., Higgins, J. P., & Kambham, N. (2016). Clinicopathologic Threshold of Acute Colorectal Graft-versus-Host Disease. ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE, 140(6), 570–77. -
Late acute graft-versus-host disease: a prospective analysis of clinical outcomes and circulating angiogenic factors
Holtan, S. G., Khera, N., Levine, J. E., Chai, X., Storer, B., Liu, H. D., … Pidala, J. (2016). Late acute graft-versus-host disease: a prospective analysis of clinical outcomes and circulating angiogenic factors. BLOOD, 128(19), 2350–58. -
An endpoint associated with clinical benefit after initial treatment for chronic graft-versus-host disease.
Martin, P. J., Storer, B. E., Inamoto, Y., Flowers, M. E. D., Carpenter, P. A., Pidala, J., … Lee, S. J. (2017). An endpoint associated with clinical benefit after initial treatment for chronic graft-versus-host disease. Blood. -
HLA-mismatched unrelated donor transplantation using TLI-ATG conditioning has a low risk of GVHD and potent antitumor activity.
Spinner, M. A., Fernández-Viña, M., Creary, L. E., Quinn, O., Elder, L., Arai, S., … Rezvani, A. R. (2017). HLA-mismatched unrelated donor transplantation using TLI-ATG conditioning has a low risk of GVHD and potent antitumor activity. Blood Advances, 1(17), 1347–57. -
Infusion of donor-derived CD8(+) memory T cells for relapse following allogeneic hematopoietic cell transplantation
Muffly, L., Sheehan, K., Armstrong, R., Jensen, K., Tate, K., Rezvani, A. R., … Lowsky, R. (2018). Infusion of donor-derived CD8(+) memory T cells for relapse following allogeneic hematopoietic cell transplantation. BLOOD ADVANCES, 2(6), 681–90. -
Phase I/II Trial for Patients with Advanced Hematologic Malignancies Undergoing Myeloablative Allogeneic HCT with a T Cell Depleted Graft with Infusion of Conventional T Cells and Regulatory T Cells
Meyer, E., Laport, G. G., Tantsura, I., Tang, S. W., Sahaf, B., Rangarajan, K., … Negrin, R. S. (2018). Phase I/II Trial for Patients with Advanced Hematologic Malignancies Undergoing Myeloablative Allogeneic HCT with a T Cell Depleted Graft with Infusion of Conventional T Cells and Regulatory T Cells. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 24(3), S145. -
Daratumumab yields rapid and deep hematologic responses in patients with heavily pretreated AL amyloidosis
Kaufman, G. P., Schrier, S. L., Lafayette, R. A., Arai, S., Witteles, R. M., & Liedtke, M. (2017). Daratumumab yields rapid and deep hematologic responses in patients with heavily pretreated AL amyloidosis. BLOOD, 130(7), 900–902. -
Potential Association of Anti-CCR4 Antibody Mogamulizumab and Graft-vs-Host Disease in Patients With Mycosis Fungoides and Sézary Syndrome.
Dai, J., Almazan, T. H., Hong, E. K., Khodadoust, M. S., Arai, S., Weng, W.-K. K., & Kim, Y. H. (2018). Potential Association of Anti-CCR4 Antibody Mogamulizumab and Graft-vs-Host Disease in Patients With Mycosis Fungoides and Sézary Syndrome. JAMA Dermatology. -
The Cost of Hematopoietic Stem-Cell Transplantation in the United States
Broder, M. S., Quock, T. P., Chang, E., Reddy, S. R., Agarwal-Hashmi, R., Arai, S., & Villa, K. F. (2017). The Cost of Hematopoietic Stem-Cell Transplantation in the United States. AMERICAN HEALTH AND DRUG BENEFITS, 10(7), 366–73. -
Anti-Platelet-Derived Growth Factor Receptor Alpha Chain Antibodies Predict for Response to Nilotinib in Steroid-Refractory or -Dependent Chronic Graft-Versus-Host Disease
Chen, G. L., Carpenter, P. A., Broady, R., Gregory, T. K., Johnston, L. J., Storer, B. E., … Miklos, D. B. (2018). Anti-Platelet-Derived Growth Factor Receptor Alpha Chain Antibodies Predict for Response to Nilotinib in Steroid-Refractory or -Dependent Chronic Graft-Versus-Host Disease. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 24(2), 373–80. -
Association of Socioeconomic Status with Chronic Graft-versus-Host Disease Outcomes
Hamilton, B. K., Rybicki, L., Arai, S., Arora, M., Cutler, C. S., Flowers, M. E. D., … Khera, N. (2018). Association of Socioeconomic Status with Chronic Graft-versus-Host Disease Outcomes. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 24(2), 393–99. -
Donor Derived MDS/AML in Patients with Germline GATA2 Mutations
Galera, P., Hsu, A., Wang, W., Schwartz, J. R., Klco, J., Arai, S., … Calvo, K. (2018). Donor Derived MDS/AML in Patients with Germline GATA2 Mutations. MODERN PATHOLOGY. NATURE PUBLISHING GROUP. -
Amphiregulin Modifies the Minnesota Acute Graft-Versus-Host Disease Risk Score: Results from BMT CTN Acute Gvhd Therapy Trials
Holtan, S. G., Defor, T. E., Howard, A., Pidala, J. A., Levine, J. E., Wu, J. M., … MacMillan, M. L. (2018). Amphiregulin Modifies the Minnesota Acute Graft-Versus-Host Disease Risk Score: Results from BMT CTN Acute Gvhd Therapy Trials. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION. ELSEVIER SCIENCE INC. -
Validation of the Hematopoietic Cell Transplantation-Specific Comorbidity Index in Nonmyeloablative Allogeneic Stem Cell Transplantation
Veeraputhiran, M., Yang, L., Sundaram, V., Arai, S., Lowsky, R., Miklos, D., … Johnston, L. (2017). Validation of the Hematopoietic Cell Transplantation-Specific Comorbidity Index in Nonmyeloablative Allogeneic Stem Cell Transplantation. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 23(10), 1744–48. -
Final results from a defibrotide treatment-IND study for patients with hepatic veno-occlusive disease/sinusoidal obstruction syndrome
Kernan, N. A., Grupp, S., Smith, A. R., Arai, S., Triplett, B., Antin, J. H., … Richardson, P. (2018). Final results from a defibrotide treatment-IND study for patients with hepatic veno-occlusive disease/sinusoidal obstruction syndrome. BRITISH JOURNAL OF HAEMATOLOGY, 181(6), 816–27. -
Amphiregulin modifies the Minnesota Acute Graft-versus-Host Disease Risk Score: results from BMT CTN 0302/0802
Holtan, S. G., DeFor, T. E., Panoskaltsis-Mortari, A., Khera, N., Levine, J. E., Flowers, M. E. D., … MacMillan, M. L. (2018). Amphiregulin modifies the Minnesota Acute Graft-versus-Host Disease Risk Score: results from BMT CTN 0302/0802. BLOOD ADVANCES, 2(15), 1882–88. -
Design and Patient Characteristics of the Chronic Graft-versus-Host Disease Response Measures Validation Study
Lee, S. J., Flowers, M. E. D., Storer, B., Onstad, L., Kurukulasuriya, C., Jagasia, M., … Jaglowski, S. (2018). Design and Patient Characteristics of the Chronic Graft-versus-Host Disease Response Measures Validation Study. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 24(8), 1727–32. -
Donor-derived MDS/AML in families with germline GATA2 mutation
Galera, P., Hsu, A. P., Wang, W., Droll, S., Chen, R., Schwartz, J. R., … Calvo, K. R. (2018). Donor-derived MDS/AML in families with germline GATA2 mutation. BLOOD, 132(18), 1994–98. -
Grading cardiac response in AL amyloidosis: implications for relapse and survival.
Eckhert, E., Witteles, R., Kaufman, G., Lafayette, R., Arai, S., Schrier, S., … Liedtke, M. (2018). Grading cardiac response in AL amyloidosis: implications for relapse and survival. British Journal of Haematology. -
A Case Report of Refractory Immune Thrombocytopenia (ITP) Following Reduced Intensity Conditioning (RIC) Hematopoietic Cell Transplantation (HCT) for Myelodysplastic Syndrome (MDS) Successfully Treated with Off-Label Use of Daratumumab
Migdady, Y., Gupta, R., Ediriwickrema, A., Socola, F., Arai, S., & Martin, B. A. (2018). A Case Report of Refractory Immune Thrombocytopenia (ITP) Following Reduced Intensity Conditioning (RIC) Hematopoietic Cell Transplantation (HCT) for Myelodysplastic Syndrome (MDS) Successfully Treated with Off-Label Use of Daratumumab. BLOOD. AMER SOC HEMATOLOGY. -
Nonmyeloablative Allogeneic Transplantation Using TLI-ATG Conditioning for Lymphoid and Myeloid Malignancies: Mature Follow-up from a Large, Single Institution Cohort
Spinner, M. A., Kennedy, V. E., Tamaresis, J. S., Lavori, P. W., Elder, L. V., Arai, S., … Lowsky, R. (2018). Nonmyeloablative Allogeneic Transplantation Using TLI-ATG Conditioning for Lymphoid and Myeloid Malignancies: Mature Follow-up from a Large, Single Institution Cohort. BLOOD, 132. -
Graded Cardiac Response Correlates with Relapse and Survival in AL Amyloidosis
Eckhert, E. K., Witteles, R., Kaufman, G., Lafayette, R., Arai, S., Schrier, S., … Liedtke, M. (2018). Graded Cardiac Response Correlates with Relapse and Survival in AL Amyloidosis. BLOOD, 132. -
Hedgehog Pathway Inhibitor for Treatment of Steroid-Refractory Sclerodermatous Chronic Graft-Versus-Host Disease (GVHD)
Gupta, R., Albabtain, A., Arai, S., Kwong, B., & Weng, W.-K. (2018). Hedgehog Pathway Inhibitor for Treatment of Steroid-Refractory Sclerodermatous Chronic Graft-Versus-Host Disease (GVHD). BLOOD. AMER SOC HEMATOLOGY. -
Elevated Axicabtagene Ciloleucel (CAR-19) Expansion By Immunophenotyping Is Associated with Toxicity in Diffuse Large B-Cell Lymphoma
Spiegel, J. Y., Sahaf, B., Hossain, N., Frank, M. J., Claire, G., Abramian, M., … Miklos, D. B. (2018). Elevated Axicabtagene Ciloleucel (CAR-19) Expansion By Immunophenotyping Is Associated with Toxicity in Diffuse Large B-Cell Lymphoma. BLOOD. AMER SOC HEMATOLOGY. -
Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduced-intensity conditioning: a randomised phase 2 trial with a non-randomised contemporaneous control group (BMT CTN 1203).
Bolanos-Meade, J., Reshef, R., Fraser, R., Fei, M., Abhyankar, S., Al-Kadhimi, Z., … Koreth, J. (2019). Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduced-intensity conditioning: a randomised phase 2 trial with a non-randomised contemporaneous control group (BMT CTN 1203). The Lancet. Haematology, 6(3), e132–e143. -
Defining a Hodgkin lymphoma population for novel therapeutics after relapse from autologous hematopoietic cell transplant.
Arai, S., Fanale, M., DeVos, S., Engert, A., Illidge, T., Borchmann, P., … Horning, S. J. (2013). Defining a Hodgkin lymphoma population for novel therapeutics after relapse from autologous hematopoietic cell transplant. Leukemia & Lymphoma, 54(11), 2531–33. -
Transplantation of donor grafts with defined ratio of conventional and regulatory T cells in HLA-matched recipients.
Meyer, E. H., Laport, G., Xie, B. J., MacDonald, K., Heydari, K., Sahaf, B., … Negrin, R. S. (2019). Transplantation of donor grafts with defined ratio of conventional and regulatory T cells in HLA-matched recipients. JCI Insight, 4(10). -
Transplantation of donor grafts with defined ratio of conventional and regulatory T cells in HLA-matched recipients
Meyer, E. H., Laport, G., Xie, B. J., MacDonald, K., Heydari, K., Sahaf, B., … Negrin, R. S. (2019). Transplantation of donor grafts with defined ratio of conventional and regulatory T cells in HLA-matched recipients. JCI INSIGHT, 4(10). -
Grading cardiac response in AL amyloidosis: implications for relapse and survival
Eckhert, E., Witteles, R., Kaufman, G., Lafayette, R., Arai, S., Schrier, S., … Liedtke, M. (2019). Grading cardiac response in AL amyloidosis: implications for relapse and survival. BRITISH JOURNAL OF HAEMATOLOGY, 186(1), 144–46. -
Nonmyeloablative TLI-ATG conditioning for allogeneic transplantation: mature follow-up from a large single-center cohort.
Spinner, M. A., Kennedy, V. E., Tamaresis, J. S., Lavori, P. W., Arai, S., Johnston, L. J., … Lowsky, R. (2019). Nonmyeloablative TLI-ATG conditioning for allogeneic transplantation: mature follow-up from a large single-center cohort. Blood Advances, 3(16), 2454–64. -
A Changing Landscape of Mortality for Systemic Light Chain Amyloidosis.
Barrett, C. D., Dobos, K., Liedtke, M., Tuzovic, M., Haddad, F., Kobayashi, Y., … Witteles, R. M. (2019). A Changing Landscape of Mortality for Systemic Light Chain Amyloidosis. JACC. Heart Failure. -
Organ responses with daratumumab therapy in previously treated AL amyloidosis.
Chung, A., Kaufman, G. P., Sidana, S., Eckhert, E., Schrier, S. L., Lafayette, R. A., … Liedtke, M. (2020). Organ responses with daratumumab therapy in previously treated AL amyloidosis. Blood Advances, 4(3), 458–66. -
Successful treatment of thrombocytopenia with daratumumab after allogeneic transplant: a case report and literature review.
Migdady, Y., Ediriwickrema, A., Jackson, R. P., Kadi, W., Gupta, R., Socola, F., … Martin, B. A. (2020). Successful treatment of thrombocytopenia with daratumumab after allogeneic transplant: a case report and literature review. Blood Advances, 4(5), 815–18. -
Allogeneic Hematopoietic Cell Transplantation for Adult Acute Lymphoblastic Leukemia: Significant Increase in Survival in the Post-Targeted Immunotherapy Era
Muffly, L., Arai, S., Johnston, L., Lowsky, R., Meyer, E. H., Miklos, D. B., … Cunanan, K. (2020). Allogeneic Hematopoietic Cell Transplantation for Adult Acute Lymphoblastic Leukemia: Significant Increase in Survival in the Post-Targeted Immunotherapy Era. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 26(3), S106. -
Outcomes in Patients With Cardiac Amyloidosis Undergoing Heart Transplantation.
Barrett, C. D., Alexander, K. M., Zhao, H., Haddad, F., Cheng, P., Liao, R., … Witteles, R. M. (2020). Outcomes in Patients With Cardiac Amyloidosis Undergoing Heart Transplantation. JACC. Heart Failure.
Clinical Trials
Clinical trials are research studies that evaluate a new medical approach, device, drug, or other treatment. As a Stanford Health Care patient, you may have access to the latest, advanced clinical trials.
Open trials refer to studies currently accepting participants. Closed trials are not currently enrolling, but may open in the future.
- Chronic GVHD Response Measures Validation »
- Acute Graft-versus-Host Disease Treatment (BMT CTN 0802) »
- Targeted Therapy of Bronchiolitis Obliterans Syndrome »
- TLI & ATG for Non-Myeloablative Allogeneic Transplantation for MDS and MPD »
- Transplantation for Patients With Chronic Lymphocytic Leukemia »
- Post-transplant Autologous Cytokine-induced Killer (CIK) Cells for Treatment of High Risk Hematologic Malignancies »
- Allogeneic HCT Using Nonmyeloablative Host Conditioning With TLI & ATG vs SOC in AML »
- Peripheral Blood Stem Cell Transplant vs Bone Marrow Transplant in Individuals With Hematologic Cancers (BMT CTN 0201) »
Practice Locations
Amyloid Center Stanford, CA
Stanford, CA
Amyloid Center
300 Pasteur Drive , 2nd Floor, Room A260
Stanford , CA 94305
Make An Appointment More Clinic Information » Getting Here »Blood and Marrow Transplant Program (BMT) - 900 Blake Wilbur Drive Palo Alto, CA
Palo Alto, CA
Blood and Marrow Transplant Program (BMT) - 900 Blake Wilbur Drive
900 Blake Wilbur Drive, 2nd Floor
Palo Alto , CA 94304
Make An Appointment More Clinic Information » Getting Here »Important Information about Our Organizations and Physician Affiliation
Stanford Health Care, Stanford Health Care Tri-Valley, and Stanford Medicine Partners are each independent nonprofit organizations that are affiliated with but separate from each other and from Stanford University. The physicians who provide care at facilities operated by Stanford Health Care, Stanford Health Care Tri-Valley, and Stanford Medicine Partners are faculty, foundation, or community physicians who are not employees, representatives, or agents of Stanford Health Care, Stanford Health Care Tri- Valley, or Stanford Medicine Partners. Stanford Health Care, Stanford Health Care Tri-Valley, and Stanford Medicine Partners do not exercise control over the care provided by such faculty, foundation, and community physicians and are not responsible for their actions.
Patient Reviews
(121 reviews)
Dr. Aria is the best! She is so caring and brilliant. I feel very fortunate that she is my doctor.
Professional and knowledgeable.
Dr Arai provides me with all necessary medical information. She answered all my questions.
It’s a pleasure to have her as my BMT Doctor.
Awesome Doctor!
She really cares about me as a patient and a person.
Wonderful person, compassionate, professional, very knowledgeable, world class.
Dr. Arai Helped save my life and is an extremely intelligent physician who clearly understood what steps to take to do so. I’m very fortunate to have her as my physician. Thank you Dr. Arai and Stanford university for all you have done for me and my family.
I appreciate her clear explanations.
Great Doctor. Very clear and concise. Easy to work with. Thank you!
Dr. Arai is the BEST Oncologist in the world!! Very caring and has a great personality.
Dr Arai was thorough and answered all of our questions. This could have been a Zoom call tho, saving us from driving 6 hrs each way and two nights in a hotel.
Fabulous care giver. Always a pleasure to discuss health issues with her.
Dr Arai and her entire team are top notch. I will be forever grateful for the care they provided me.
She's great!
Great doctor! Thorough and patient with all my questions. I am 8 years post BMT and I appreciate her explaining what was happening to me pre and post transplant, to get me stable and healthy! Love her, Sandy, Dr. Kwan and BMT staff - all great!
Sally Arai is wonderful, brilliant and caring. I am so happy to be in her care!
Excelente Dr
Dr. Arai was very clear in the next steps of my treatment which is great for me. She was thorough and the appointment was excellent.
Dr Arai and Dr. Singh were informative and caring
Dr. Arai and her team are excellent and inspire confidence that my medical issues will resolve in a positive outcome. It is also very comforting to know that Dr. Arai listens to my concerns and is very attentive to my questions. I feel fortunate that Dr. Arai and her team are providing the highest level of medical guidance and care for my health challenges.
The medical team in the oncology department is outstanding. They saved my life.
She and Sandy are awesome!
Dr. Arai is caring and diligent and I feel I am in the best care for my post transplant odyssey.
She’s awesome!
She is knowledgeable and cares a great deal about her patients. I like her very much.
She is thorough and answered all my questions I am very happy that doctor Arai is my doctor
I like the way she thinks and makes decisions with confidence, which in turn reassures me that we are on a good track.
Nice and very knowledgeable
She is both professional and personable, a rare combination.
Thanks 😊
Dr. Arai and Sandy are an amazing team. So caring and understanding, I appreciate them both so much.
She is interested and very quick to get up to speed. We always have good conversations.
Dr. Arai is extremely knowledgeable, thorough, and kind. Her experienced care gives me confidence that I will be given the most up-to-date information and options for improving my health issues.
Appointment itself was great.
An excellent professional.
Dr Arai is an excellent Dr . She’s really care and compassion for her patient.
Outstanding physician and a very kind person.
Dr. Arai and Sandy Burgess are the best.
She is super smart and very down to Earth. I am very fortunate she is my Dr.
Dr. Arai is amazing! I feel extremely blessed to have her as my doctor. She is caring, a good listener, extremely patient and knowledgeable. I trust her with my life , she had taken such great care of me, she saved my life and I am extremely grateful ♥ï¸
Dr. Sally Arai explained everything very well.
Best of the best!
Dr. Sally Arai is a wonderful physician. She's compassionate, patient & expert in her medical advice. She epitomizes all that is good in this world. She's always there to help her patients. Thank you, Dr. Arai.
Dr Arai, compassionate, great integrity & knowledge.
Dr. Arai and staff saved my life, I am extremely grateful to them.
Dr. Sally Arai... grace, humility, brilliance, and compassion, an inextinguishable spark of Divine Fire and HOPE. Her medical care is excellent. Her patient advocacy is unwavering.
Provider did seem always behind, by the time she came to use - each time 30 mins.+ late. She seemed in a hurry during our visit.
The best doctor ever!
Dr. Sally Arai is an excellent clinician and has a great sense of humor.
Dr. Arai is incredible - she is a real asset to Stanford. I would put her in the "excellent" category. I am at 800 days post-transpalnt today. I trust her with my life. I follow her treatment requirements to the letter.
Very flexible and accommodating. Very informative meeting.
Dr. Arai saved my life.
Dr. Arai is an exceptional physician.
Both Dr. Sally Arai and Dr. Tamna Wangjam give me great information. All questions are discussed & answered in terms I can understand. I'm very fortunate I have them providing me my treatment!! Thank you.
Wonderful experience, focused, fast, and friendly.
I feel very comfortable with Dr. Arai.
Staff is tops in their craft, supplying great education & concerns with a friendly upbeat attitude.
Dr. Arai is an exceptional physician.
Dr. Sally Arai explains my treatment plan very well. She is great at finding alternative medicines when necessary. Dr. Arai & Sandy Burgess are outstanding. I am blessed, because they have exhibit a passion in my BMT treatment & care.
Wonderful conversations with excellent education and instruction, answering any and a questions and concerns with confidence.
Dr. Arai explains topics in a logical & understandable manner. She is a great listener, answering questions my wife and I have. She's a great doctor and representative for the Stanford BMT Department. - Dr. Sally Arai.
Dr. Sally R Arai is a superlative physician. Extraordinary patient manner, attentive & very humble. She is expert in her advice. I am so fortunate to have such an extraordinary doctor treat me. I completely trust her & she is a super listener. Dr. Sally R Arai is a "NATIONAL TREASURE!"
Too busy, overloaded, scattered. Losing my confidence.
I feel very comfortable with Dr. Arai. We are two years into a very successful bone marrow transplant.
Dr. Arai is wonderful. Explains medical things in a manner easily understood. Her demeanor exhibits professionalism and confidence. Very reassuring to me. Dr. Arai is a valuable member of the BMT team.
Excellent describes everything in summary & detail.
Cecelia was delightful.
Good.
I was extremely impressed by Dr. Arai in every regard. She is a very caring physician, highly knowledgeable, and excellent communicator. She was very patient, gave me all the time I needed.
Dr. Arai seems to care she has been keeping me alive since 2015.
Best dr. ever. Dr. Arai has so much compassion and love for her patients.
Dr. Arai is a good experience.
Highly profession, thorough education and complete answers to question, quality time is alway conducted.
Very good experience.
Dr. Sally Arai is the most wonderful, compassionate & brilliant physician I have ever had treating me. Truly excellent, caring & humble. Thank God for Dr. Sally Arai. I wish every person could be treated by a physician like her. Truly "EXCELLENT" "SPECIAL".
Very satisfy.
Great job at delivering not so great news - compassionate & educational.
Excellent.
Professor Sally Aria take pride in assisting patients comprehend their medical issues taking the frustrating out of their concerns.
Dr. took time to answer what few questions we had.
Dr. Sally Arai is a truly brilliant, compassionate physician. She listened to and treated me with utmost respect & kindness. She is a treasure to the world. I am utterly grateful for the expert medical care she has given me - Any person receiving her care is extremely fortunate. Thank you! BEYOND EXCELLENT!
I don't think I could have found a better caring team. Dr. S. Arai makes a difficult situation, easier to follow and understand. Every decision is made by "us"! Gayla Knight is a beautiful wonderful person. Always there for you and quick with a hug when needed. We just love her.
Doctor Sally Aria is a perfect example and role model for all health care providers to follow. I feel confident and safe as her patient.
Dr. Arai always makes me feel good if something comes up between visit I can't wait to see her.
I love Dr. Arai - Initially she was a little quiet but so happy with my outcomes - She answers every question no matter how silly - professionally! Thank you for giving me my life back!
Dr. Sally Arai & her staff were truly attentive, brilliant & compassionate to me. I am truly grateful to DR. SALLY ARAI, a WONDERFUL brilliant physician & human being!
Dr. Arai is very good to me I believe she saved my life.
Dr. Aria and her team are close to the top of their game.
Professor Sally Aria, the best doctor I have ever met!
Dr. Arai is the best. Dr. Amy Nelson (Kaiser) and Dr. Arai saved my life.
Good experience - Since being - admitted in July I think everything has gone better than expected thanks to Sally Arai MD and Laura Jean Johnston MD.
Excellent.
Dr. Arai is excellent. Very easy to talk with. Very knowledgeable and follows through.
Dr. Arai is an outstanding doctor.
Only good experiences.
Dr. Arai always gives me the time needed to address all of my issues. I am very confident in her care.
Dr. seemed interested in impressing me with hyper-technical explanations.
Good.
Dr. Arai is great!! The team from Stanford and San Francisco Dr. Amy Nelson saved my life.
Dr. Arai is kind & intelligent - Sometimes gets too technical.
Not prepared, had not checked my record for previous tests, was vague about future treatment.
The staff is average in building relationships, always educating me with confidence and comfort for my concerns. Our appointment is complete when I have finished the appointment with all my concerns answered with complete satisfaction.
Dr. Arai is amazing!
Dr. Arai provides thoughtful, insightful care. I could not be in better hands in terms of medical care and guidance.
Sally Arai MD is a superior doctor on the best I have ever met. She helps Stanford look great!
Staff has a built-in checklist that works with excellence.
Dr. Arai is exceptional! Extraordinary knowledge, expertise, analytical/decision making, excellent communications caring, compassionate. She is the BEST!!
Excellent educator, thorough follow-up on all criteria of my health.
Dr. Arai is not only the greatest provider I ever met, but also the greatest person I ever met!
Dr. Arai great - I feel I am in good hands.
Dr. Arai is a world class physician!! She excels in every way - expertise, application of knowledge, dedication, communication, patient care.
Dr. Arai is wonderful!
The experience was very comforting.
I was sent to ITA upstairs. This was the second time in a month no orders were written and I had to wait for another doctor to write orders.
This was a great visit. We have a lot of confidence in the doctor and staff.
The most excellent provider in the universe.
Dr. Sally Arai is an experienced, competent, kind and helpful doctor.
I have great confidence in Dr. Arai - she remembers everything concerning my care.
Great doctor!
I told the doctor the she need to speak because I had poor hearing (hearing aids in both ears) the doctor continually lowered her voice to nearly a whisper I probably missed 50% of what she said.
She was friendly and approachable.
View More »
Referring Physicians
PHYSICIAN HELPLINE
Phone: 1-866-742-4811
Fax: 650-320-9443
Monday–Friday, 8 a.m.–5 p.m.
Fax: 650-320-9443
Monday–Friday, 8 a.m.–5 p.m.
Stanford Health Care provides comprehensive services to refer and track patients, as well as the latest information and news for physicians and office staff. For help with all referral needs and questions, visit Referring Physicians.
You may also submit a web referral or complete a referral form and fax it to 650-320-9443 or email the Referral Center at ReferralCenter@stanfordhealthcare.org.
- Send referrals online
- View referral status
- Access medical records